middl
east
respiratori
syndrom
coronaviru
merscov
infect
human
highli
lethal
fatal
rate
new
prophylact
therapeut
strategi
combat
human
infect
urgent
need
isol
fulli
human
neutral
antibodi
human
survivor
antibodi
recogn
receptorbind
domain
merscov
glycoprotein
interfer
interact
viral
human
cellular
receptor
human
dipeptidyl
peptidas
knowledg
studi
first
report
human
neutral
monoclon
antibodi
complet
inhibit
merscov
replic
common
marmoset
monotherapi
repres
potenti
altern
treatment
human
infect
merscov
worthi
evalu
clinic
set
middl
east
respiratori
syndrom
coronaviru
merscov
first
isol
sputum
saudi
arabian
male
patient
eventu
die
acut
pneumonia
past
year
viru
spread
across
countri
result
infect
death
mortal
rate
approxim
largest
outbreak
south
korea
caus
case
infect
includ
death
thu
far
report
case
link
travel
resid
countri
near
arabian
peninsula
dromedari
camel
camelu
dromedariu
regard
natur
reservoir
neutral
antibodi
viral
rna
detect
accord
nationwid
serolog
test
qatar
saudi
arabia
proport
seroposit
antibodi
significantli
higher
camelexpos
individu
gener
popul
nucleotid
fragment
almost
ident
viral
genom
also
identifi
bat
saudi
arabia
africa
suggest
likelihood
bat
origin
merscov
find
demonstr
bat
coronaviru
phylogenet
close
relat
merscov
capabl
use
cellular
receptor
also
support
possibl
human
dipeptidyl
peptidas
also
call
character
cellular
receptor
merscov
studi
shown
antibodi
receptorbind
domain
rbd
inhibit
viral
infect
cell
express
mice
fulllength
protein
induc
product
neutral
antibodi
merscov
virusneutr
activ
also
observ
polyclon
antibodi
mice
immun
truncat
rbd
protein
merscov
one
threaten
pathogen
like
caus
major
epidem
futur
priorit
world
health
organ
blueprint
research
develop
effort
develop
countermeasur
although
ribavirin
interferon
exhibit
antimerscov
activ
vitro
allevi
diseas
symptom
test
rhesu
macaqu
human
patient
licens
treatment
vaccin
merscov
infect
current
avail
new
prevent
therapeut
strategi
urgent
need
counter
global
threat
use
viral
rbd
bait
scientist
also
character
sever
monoclon
antibodi
mab
potent
neutral
activ
merscov
nonimmun
human
antibodi
librari
particular
human
mab
direct
protein
rbd
describ
potent
neutral
activ
vitro
efficaci
rabbit
present
studi
isol
fulli
human
neutral
antibodi
merscov
peripher
b
cell
convalesc
donor
surviv
merscov
infect
report
first
evid
neutral
mab
complet
inhibit
merscov
replic
nonhuman
primat
prophylact
therapeut
thu
show
promis
prophylact
therapeut
treatment
human
case
merscov
infect
use
human
peripher
blood
sampl
review
approv
ethic
committe
institut
pathogen
biolog
chines
academi
medic
scienc
peke
union
medic
colleg
patient
sever
merscov
infect
diagnos
laboratori
confirm
reversetranscript
polymeras
chain
reaction
hospit
huizhou
peopl
hospit
guangdong
provinc
china
convalesc
blood
sampl
collect
written
inform
consent
obtain
anim
experi
approv
institut
anim
care
use
committe
institut
laboratori
anim
scienc
peke
union
medic
colleg
perform
follow
chines
nation
guidelin
care
laboratori
anim
approv
institut
anim
care
use
committe
institut
laboratori
anim
scienc
protocol
experi
live
merscov
perform
accord
standard
oper
procedur
biosafeti
level
facil
describ
elsewher
merscov
strain
kind
gift
r
fouchier
subsequ
propag
vero
cell
american
type
cultur
collect
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
calf
serum
penicillin
streptomycin
tissu
cultur
infecti
dose
tcid
per
millilit
determin
merscov
vero
cell
describ
elsewher
antimerscov
phage
antibodi
librari
gener
describ
elsewher
briefli
heavi
light
chain
gene
amplifi
complementari
dna
use
polymeras
chain
reaction
sequenti
clone
phagemid
vector
phage
librari
gener
antibodi
librari
screen
round
pan
purifi
merscov
virion
antibodi
serial
dilut
step
dmem
contain
fetal
calf
serum
inactiv
minut
subsequ
tcid
merscov
combin
dilut
incub
hour
mixtur
total
ad
vero
cell
plate
incub
hour
carbon
dioxid
plate
wash
replac
dmem
incub
score
cytopath
effect
day
experi
perform
biosafeti
level
condit
experi
involv
common
marmoset
perform
describ
elsewher
slight
modif
approv
institut
anim
care
use
committe
briefli
total
healthi
male
common
marmoset
callithrix
jacchu
year
old
g
randomli
assign
group
measur
prophylact
efficaci
common
marmoset
per
group
intraperiton
inocul
mgkg
purifi
hour
intratrach
challeng
tcid
merscov
dmem
ketamin
anesthesia
three
addit
common
marmoset
infect
use
model
group
common
marmoset
observ
daili
sign
diseas
mortal
day
therapi
mer
diseas
common
marmoset
intratrach
infect
tcid
merscov
dmem
subsequ
passiv
immun
mgkg
purifi
hour
later
follow
daili
observ
sign
diseas
death
day
anim
observ
twice
daili
clinic
sign
score
use
describ
clinic
score
system
describ
elsewher
includ
evalu
gener
appear
skin
fur
appear
discharg
oral
nasal
andor
ocular
respiratori
rate
food
consumpt
definit
clinic
score
provid
supplementari
tabl
clinic
examin
present
studi
includ
measur
bodi
temperatur
twice
daili
bodi
weight
hour
infect
necropsi
schedul
hour
infect
clinic
score
describ
elsewher
necropsi
tissu
collect
histopatholog
viral
load
studi
histopatholog
perform
marmoset
lung
tissu
lung
tissu
sampl
lobe
resect
formalinfix
tissu
lung
fix
neutral
buffer
formaldehyd
embed
paraffin
tissu
section
stain
hematoxylineosin
analyz
microscop
lung
patholog
find
record
pathologist
blind
experiment
design
describ
elsewher
find
note
includ
peribronchiol
inflammatori
cell
primarili
lymphocyt
surround
bronchiol
perivascul
inflammatori
cell
primarili
lymphocyt
surround
blood
vessel
interstiti
pneumon
increas
thick
alveolar
wall
associ
inflammatori
cell
primarili
neutrophil
alveol
inflammatori
cell
primarili
neutrophil
macrophag
within
alveolar
space
viral
titer
independ
evalu
infect
common
marmoset
result
present
mean
standard
deviat
statist
analysi
perform
use
ssp
softwar
version
differ
consid
statist
signific
p
purifi
merscov
rbd
fab
concentr
mgml
hepesbuff
salin
buffer
mmoll
hepe
ph
mmoll
sodium
chlorid
viral
rbd
protein
fab
mix
incub
ice
hour
subsequ
purifi
mean
size
exclus
chromatographi
superdex
ge
healthcar
complex
collect
concentr
approxim
mgml
crystal
screen
crystal
success
realiz
reservoir
solut
contain
moll
citric
acid
moll
bistri
propan
wtvol
polyethylen
glycol
cryoprotect
prepar
ad
ethylen
glycol
well
solut
diffract
data
crystal
collect
beam
line
shanghai
synchrotron
research
facil
diffract
imag
index
integr
scale
use
softwar
structur
determin
molecular
replac
method
use
program
phaser
version
search
model
merscov
rbd
protein
data
bank
pdb
code
initi
molecular
replac
structur
variabl
constant
domain
heavi
light
chain
avail
pdb
file
show
highest
sequenc
ident
iter
refin
phenix
program
version
model
build
coot
crystallograph
objectori
toolkit
coot
program
perform
complet
structur
refin
structur
valid
perform
use
program
procheck
structur
figur
creat
use
pymol
version
structur
refin
statist
list
tabl
crystal
structur
complex
merscov
rbd
deposit
pdb
access
code
two
fab
phage
display
librari
light
chain
establish
one
fab
antibodi
strongli
react
antigen
initi
isol
convert
fulllength
human
immunoglobulin
light
chain
heavi
chain
v
h
potenti
neutral
activ
merscov
assess
shown
figur
neutral
merscov
cell
dosedepend
manner
show
potent
neutral
activ
complet
inhibit
live
viral
replic
explor
prophylact
efficaci
common
marmoset
intraven
inocul
antibodi
dose
mgkg
design
mgkg
challeng
merscov
hour
later
control
group
simultan
infect
set
model
group
clinic
sign
temperatur
chang
bodi
weight
chang
marmoset
monitor
daili
sever
diseas
develop
model
anim
increas
respiratori
rate
reduc
movement
loss
appetit
soon
hour
viral
infect
shown
figur
mean
clinic
score
group
anim
hour
infect
reach
hour
infect
mean
clinic
score
group
less
group
particularli
group
end
monitor
period
mean
clinic
score
common
marmoset
nearli
less
group
mean
bodi
temperatur
common
marmoset
peak
hour
infect
figur
contrast
mean
temperatur
group
gradual
chang
remain
nearli
normal
bodi
temperatur
end
experi
figur
result
viral
infect
common
marmoset
show
bodi
weight
loss
infect
day
infect
group
show
bodi
weight
loss
compar
loss
respect
group
figur
taken
togeth
result
demonstr
prophylact
immun
substanti
improv
clinic
outcom
common
marmoset
infect
merscov
clarifi
clinic
relev
effect
antivir
therapi
merscov
infect
common
marmoset
initi
intratrach
infect
tcid
merscov
follow
intraven
inocul
hour
mgkg
efficaci
treatment
determin
hour
infect
mean
clinic
score
group
compar
group
lower
score
group
figur
mean
bodi
temperatur
chang
shown
figur
group
mean
bodi
temperatur
chang
much
entir
experi
wherea
group
mean
bodi
temperatur
peak
hour
infect
similarli
common
marmoset
show
bodi
weight
loss
respons
viral
infect
howev
group
receiv
treatment
earlier
lost
bodi
weight
compar
approxim
common
marmoset
group
figur
result
demonstr
even
inocul
infect
improv
circumst
common
marmoset
merscov
infect
histopatholog
detect
demonstr
model
group
show
sever
multifoc
coalesc
acut
bronchointerstiti
pneumonia
figur
pulmonari
alveoli
infiltr
signific
amount
inflammatori
cell
predominantli
consist
macrophag
neutrophil
lymphocyt
alveolar
interstitium
thicken
edema
fibrin
hemorrhag
contrast
common
marmoset
receiv
treatment
exposur
show
mild
moder
bronchointerstiti
pneumonia
small
amount
inflammatori
cell
infiltr
edema
hemorrhag
figur
expectedli
mean
viral
titer
high
common
marmoset
highest
viral
titer
log
tcid
per
gram
detect
lobe
lung
viral
titer
also
log
tcid
trachea
figur
contrast
viral
titer
detect
anim
result
demonstr
substanti
inhibit
merscov
replic
vivo
elucid
neutral
mechan
epitop
vaccin
develop
crystal
merscov
rbd
complex
success
obtain
solv
resolut
supplementari
tabl
sever
round
refin
manual
model
build
work
r
factor
rfree
valu
final
atom
model
respect
one
rbd
complex
obtain
crystallograph
asymmetr
unit
bind
ratio
model
ethylen
glycol
molecul
exist
heavi
light
chain
moreov
nglycan
nacetyldglucosamin
mannos
link
togeth
subsequ
attach
residu
rbd
figur
antibodi
form
direct
contact
receptorbind
site
rb
subdomain
rbd
complementaritydetermin
region
cdr
surround
site
figur
heavi
light
chain
primarili
contribut
paratop
via
cdr
buri
surfac
area
approxim
viral
ligand
heavi
chain
light
chain
obvious
heavychain
variabl
domain
contribut
major
bind
surfac
shown
figur
cdr
heavi
chain
form
hydrophob
caviti
encompass
epitop
rb
interact
residu
fab
includ
two
salt
bridg
form
residu
epitop
rb
consist
strand
long
loop
short
loop
superimpos
rbd
previous
report
structur
human
rbd
complex
pdb
code
shown
figur
human
interact
viral
rbd
domain
fab
epitop
surfac
gener
steric
clash
upsid
strand
rb
bind
interfac
fab
larg
overlap
site
recent
year
continu
emerg
zoonot
virus
pose
seriou
global
threat
public
health
sever
acut
respiratori
syndrom
coronaviru
merscov
ebola
zika
unfortun
develop
vaccin
antivir
agent
time
consum
lag
promot
antibodi
product
technolog
human
antibodi
gain
use
demonstr
secur
effect
previous
group
isol
neutral
antibodi
patient
recov
infect
report
gener
fulli
human
neutral
antibodi
bind
merscov
rbd
provid
first
evid
complet
inhibit
merscov
replic
nonhuman
primat
result
shown
sever
area
bronchointerstiti
pneumonia
improv
certain
degre
except
vivo
data
associ
use
convalesc
plasma
mab
treatment
mer
lack
previou
studi
primarili
focus
mous
model
transduc
adenoviru
vector
express
human
receptor
evalu
effect
antibodi
mer
infect
howev
nonhuman
primat
model
faith
mimic
human
diseas
maximum
extent
provid
better
understand
pathogenesi
merscov
human
effect
model
evalu
efficaci
potenti
treatment
strategi
antibodi
isol
nonimmun
human
phage
antibodi
librari
knowledg
antibodi
merscovneutr
antibodi
examin
rhesu
monkey
result
mild
selflimit
diseas
treatment
reduc
lung
patholog
infect
rhesu
monkey
howev
viral
rna
undetect
model
neutral
antibodytr
anim
precis
vivo
inhibitori
effect
antibodi
remain
hard
determin
neutral
antibodi
merscov
survivor
capabl
higher
neutral
activ
show
potenc
howev
antim
efficaci
primat
yet
report
anoth
nonhuman
primat
model
common
marmoset
develop
marmoset
intratrach
infect
merscov
model
support
viral
growth
show
evid
histolog
lesion
progress
sever
pneumonia
high
viral
titer
lung
trachea
mimick
sever
mer
diseas
human
ensur
better
preclin
analysi
treatment
proceed
clinic
trial
human
present
studi
also
took
advantag
common
marmoset
assess
prophylact
therapeut
efficaci
group
develop
seriou
mer
diseas
suffer
fever
notic
bodi
weight
loss
treatment
exposur
viral
infect
improv
clinic
patholog
featur
infect
marmoset
viral
titer
detect
anim
day
infect
prophylact
therapeut
experi
contrast
mean
viral
titer
lobe
lung
reach
peak
valu
day
infect
log
tcid
per
gram
group
result
prophylact
experi
show
benefici
prevent
mer
outbreak
serv
prophylact
highrisk
individu
expos
merscov
treatment
dose
effect
larg
inoculum
volum
requir
viral
replic
titer
import
cours
diseas
develop
previou
studi
viral
replic
complet
inhibit
howev
result
present
studi
show
viral
replic
could
complet
inhibit
use
common
marmoset
preliminari
research
data
show
marmoset
infect
merscov
exhibit
obviou
focal
pneumonia
hour
present
studi
model
common
marmoset
also
show
sever
patholog
chang
lung
day
infect
anim
sever
area
bronchointerstiti
pneumonia
improv
certain
degre
histopatholog
detect
also
show
effect
highdos
prophylaxi
group
mgkg
better
lowdos
prophylaxi
group
mgkg
effect
therapeut
group
hour
infect
better
therapeut
group
hour
thu
propos
histopatholog
chang
lung
associ
dose
cours
conclus
suppress
merscov
replic
reduc
inflammatori
respons
certain
degre
find
could
appli
futur
clinic
studi
previou
studi
shown
neutral
mab
primarili
target
rbd
merscov
spike
glycoprotein
site
viral
rbd
separ
major
bind
patch
structur
analysi
rbd
interact
reveal
bind
interfac
almost
complet
encompass
patch
rbd
among
residu
primarili
bound
light
chain
residu
involv
interact
heavi
chain
moreov
residu
rbd
form
hydrophob
caviti
interact
surround
residu
heavi
chain
plausibl
form
hydrogen
bond
epitop
rbd
occupi
bind
site
interf
viral
recognit
human
cellular
receptor
summari
complet
inhibit
merscov
replic
nonhuman
primat
prophylact
therapeut
treatment
consid
promis
candid
clinic
trial
reflect
safeti
potent
neutral
activ
excel
perform
vivo
thu
propos
play
import
role
prevent
merscov
infect
warrant
develop
medic
countermeasur
merscov
infect
supplementari
materi
avail
journal
infecti
diseas
onlin
consist
data
provid
author
benefit
reader
post
materi
copyedit
sole
respons
author
question
comment
address
correspond
author
